Revision of Full-Year Earnings Forecast　 (As of end of January, 2025)

With regard to the consolidated earnings forecast for the fiscal year ending March 2025 announced on April 30, 2024, we have made the following revisions in light of factors such as the recording of impairment losses on some stores in the Dispensing Pharmacy Business as extraordinary losses in the third quarter accounting period.

 

(Reason for revision to earnings forecast)

The consolidated full-year earnings forecast for the year ending March 31, 2025 have been revised due to the recording of an impairment loss on the fixed assets of the dispensing pharmacy business as an extraordinary loss due to a decline in profitability caused by the change of the business environment.

(million yen)　
FY2024
Results		 FY2025
Forecasts		 FY2025
Revised
Forecast		 Forecast
Change(%)
Net sales 340,310 373,800 373,800 ー
Operating profit 9,142 6,400 6,400 ー
Ordinary profit 9,439 6,500 6,500 ー
Profit attributable to
owners of parent		 2,553 3,700 2,000 (45.9%)